52 Week Range
As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay
Aug 5 (Reuters) - Sosei Group Corp <4565.T>::SOSEI HEPTARES AND TAKEDA ENTER INTO NEW STRATEGIC MULTI-TARGET RESEARCH, DEVELOPMENT AND COMMERCIALIZATION PARTNERSHIP.CO IS ELIGIBLE TO RECEIVE UP TO $26 MILLION IN UPFRONT, NEAR-TERM PAYMENTS, IN ADDITION TO RESEARCH FUNDING OVER AGREEMENT TERM.
May 24 (Reuters) - Sosei Group Corp <4565.T>::SOSEI HEPTARES NOTES THAT A VALID MARKETING AUTHORIZATION APPLICATION FOR QVM149, A POTENTIAL NEW INHALED COMBINATION THERAPY FOR ASTHMA, HAS BEEN FILED WITH EUROPEAN MEDICINES AGENCY.MAA FILING HAS TRIGGERED A $2.5 MILLION PAYMENT TO SOSEI HEPTARES FROM NOVARTIS.
Jan 7 (Reuters) - Sosei Group Corp <4565.T>::NOTIFIED BY ASTRAZENECA IT REACHED CLINICAL DEVELOPMENT MILESTONE WITH PARTNERED NEXT GENERATION IMMUNO-ONCOLOGY CANDIDATE AZD4635.SOSEI HEPTARES TO GET US$15 MILLION MILESTONE PAYMENT FROM ASTRAZENECA WITH FIRST PARTNERED PROGRAM MOVING TOWARDS PHASE 2.
Sept 25(Reuters) - Sosei Group Corp <4565.T>:Says its wholly-owned Japanese subsidiary Sosei Co., Ltd., has received the approval in Japan for ORAVI ® Mucoadhesive Tablets 50mg.
May 16 (Reuters) - Sosei Group Corp <4565.T>:Says it appoints Ernst & Young ShinNihon LLC as new corporate auditor, to replace Deloitte Touche Tohmatsu LLC , effective June 22 .
April 24 (Reuters) - Sosei Group Corp::STATEMENT RE PRESS COMMENT.CONFIRMS THAT IT DOES NOT INTEND TO MAKE AN OFFER FOR VECTURA.SOSEI WILL, EXCEPT WITH CONSENT OF UK PANEL ON TAKEOVERS AND MERGERS, BE BOUND BY RESTRICTIONS CONTAINED IN RULE 2.8 OF CODE.
March 13 (Reuters) - Sosei Group Corp <4565.T>:Says co has regained worldwide rights from Teva Pharmaceutical Industries Ltd., to develop and commercialize lead candidate HTL0022562 and other novel small molecule CGRP antagonists for the treatment of migraine and other severe headaches.
Nov 20 (Reuters) - Sosei Group Corp <4565.T>:Says it will issue new shares of its common stock via overseas offering, with the issue price of 10,800 yen per share (22.36 billion yen in total) and paid-in price of 10,283.55 yen per share (21.29 billion yen in total).Says payment date on Nov. 27.Previous news was disclosed on Nov. 10.
Nov 10(Reuters) - Sosei Group Corp <4565.T>:Says it plans to issue 2.1 million new shares through overseas offering .Proceeds to be mainly used for drug discovery and research and development related fund .
Nov 9(Reuters) - Sosei Group Corp <4565.T>:Says it gains a licence to develop and commercialise HTL0018318, a novel muscarinic M1 receptor agonist, in Japan as a potential new treatment for patients with dementia with Lewy bodies (DLB).Says it will undertake a Phase 2 proof-of-concept monotherapy study, expected to begin in Japan in 2018 .
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.